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Problem Definition
Multiple studies (e.g. EMPA-REG, CANVAS) demonstrate that 
SGLT2 Inhibitors (Inh) improve cardiac outcomes in patients with 
Type II Diabetes (DM2) with comorbid Cardiovascular Disease 
(CVD) including Heart Failure and Coronary Artery Disease.
SGLT2 Inhibitors are considered standard of care for patients with 
DM2 and CVD.
Based on literature published in European Journal of Preventative 
Cardiology and JACC HF, our prediction is that physicians at 
Thomas Jefferson University Hospital Ambulatory Practices (TJUH) 
under-utilize SGLT2 Inh for patients with co-morbid CVD and 
DM2.
Aims For Improvement
Process: # patient charts reviewed by Endo CRNP,  # patients 
initiated on SGLT2 Inh while inpatient
Outcome: % physicians comfortable prescribing SGLT2 Inh, # 
patients who are being prescribed SGLT2 Inh
Balancing: medication affordability, education fatigue, 
availability for education
Lessons Learned & Next Steps/Future InterventionsWithin the Jefferson Healthcare System, we sought to determine:
1. The percentage of patients with an indication for an SGLT2 
Inhibitor who were actually being prescribed this.
2. How often providers within the Jefferson system were 
prescribing these medications, and what the barriers to 
prescribing are. 
With this information, we hoped to increase the percentage of 
(qualifying) patients who are on these medications as part of 




What We Found: 100 patients met inclusion criteria:
§ 50 patients were seen by endocrinology and met criteria to be 
on SGLT2. 10/50 (20%) were on SGLT2 inhibitors.
§ 95 patients were seen by cardiology and met criteria to be on 
SGLT2. 11/95 (11.6%) were on SGLT2 inhibitors.
§ 8 patients were seen by internal medicine and met criteria to 
be on SGLT2, 0/8 (0%) were on SGLT2 inhibitors.
§ 13 patients were seen by only family medicine and met criteria 
to be on SGLT2, 1/13 (7.7%) was on SGLT2 inhibitors.
* In total 100 patients qualified for SGLT2 inhibitor 
therapy. 13/100 (13%) were on SGLT2 inhibitors.
Part 2:  
1. We collected a random sample of patients (n=200) known to 
any of the above departmental TJUH outpatient clinics.
2. We performed a retrospective chart review to determine the 
percentage of patients with DM2 and CVD (heart failure, 
coronary artery disease) who were appropriately prescribed an 
SGLT2 Inhibitor.
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Part 1: We surveyed physicians from Cardiology, 
Internal Medicine, Family Medicine, and 
Endocrinology to assess:
- physician comfort level and frequency of prescribing 
SGLT2 Inh
- subjective importance of SGLT2 Inh in patients with 
DM2 and CVD
- which medical specialties should prescribe SGLT2 Inh
Measurement Strategy
Methods/Results, Continued
SGLT2 Inhibitors in Patients with Diabetes and Cardiovascular Disease
Cristina Calogero, MD1, Jillian Cooper, MD1, Mathew Francis, MD1, Joseph Grogg, MD1, Shuwen Lin, MD1 
Patrick Prior, MD1 , Bo Hyung Yoon MD1 , Yair Lev, MD2
1. Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA
2. Division of Cardiology, Department of Medicine, Thomas Jefferson University, Philadelphia, PA
What Was Implemented?
- Creation of a cardiac metabolic task force led by Cardiology and 
Endocrinology with a goal to work collaboratively to increase 
the rate of the SGLT2 Inhibitor use in these target populations.
- Informational Card was posted in outpatient offices.
Lessons Learned: Provider comfort levels, improvement takes time 
and requires “buy-in”, may need a change in culture, an 
individual’s comfort level/awareness strongly drives outcomes.
Next Steps/Work in Progress:
- June 2020: dedicated Endocrine CRNP funded by ADA to work 
in Cardiology reviewing patient charts for SLT2 Inh indication.
- Two SGLT2 Inhibitors will be on formulary
- Endocrinologists working with Cardiology/IM/Nephrology-
lectures, Q&A
- Collaborations with ADA
* One year from the time changes are implemented, the survey and 
patient data will be repeated and re-analyzed to determine if we 
met our aim for improvement *
